Suono Bio said today that Fujifilm (TSE:4901) made an undisclosed investment in the company to support its next-gen technology intended for the rapid, formulation-independent administration of therapeutics.
The Cambridge, Mass.-based company, formed last year by researchers out of the Massachusetts Institute of Technology and Brigham & Women’s Hospital, is developing technology intended for the rapid local administration of therapeutics intended to treat serious diseases.
Read the whole story on our sister site, Drug Delivery Business News
The post Fujifilm backs therapeutic administration dev Suono Bio appeared first on MassDevice.
from MassDevice https://ift.tt/2NVsc56
Cap comentari:
Publica un comentari a l'entrada